U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    109.69
    +1.26 (+1.16%)
     
  • Gold

    1,809.40
    +7.90 (+0.44%)
     
  • Silver

    19.75
    +0.09 (+0.45%)
     
  • EUR/USD

    1.0456
    +0.0029 (+0.28%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • GBP/USD

    1.2156
    +0.0053 (+0.44%)
     
  • USD/JPY

    135.4920
    +0.3170 (+0.23%)
     
  • BTC-USD

    19,687.45
    +656.77 (+3.45%)
     
  • CMC Crypto 200

    426.82
    +6.68 (+1.59%)
     
  • FTSE 100

    7,257.21
    +88.56 (+1.24%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So should Altimmune (NASDAQ:ALT) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.

See our latest analysis for Altimmune

How Long Is Altimmune's Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Altimmune last reported its balance sheet in March 2021, it had zero debt and cash worth US$227m. Importantly, its cash burn was US$54m over the trailing twelve months. Therefore, from March 2021 it had 4.2 years of cash runway. There's no doubt that this is a reassuringly long runway. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Well Is Altimmune Growing?

It was quite stunning to see that Altimmune increased its cash burn by 356% over the last year. On the bright side, at least operating revenue was up 35% over the same period, giving some cause for hope. Considering both these metrics, we're a little concerned about how the company is developing. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Altimmune To Raise More Cash For Growth?

While Altimmune seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Altimmune has a market capitalisation of US$357m and burnt through US$54m last year, which is 15% of the company's market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

So, Should We Worry About Altimmune's Cash Burn?

On this analysis of Altimmune's cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. Separately, we looked at different risks affecting the company and spotted 4 warning signs for Altimmune (of which 2 shouldn't be ignored!) you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.